College of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210029, China.
J Ethnopharmacol. 2012 May 7;141(1):96-103. doi: 10.1016/j.jep.2012.02.005. Epub 2012 Feb 10.
Salvia miltiorrhiza Bunge named Danshen in China has been used for hundreds of years in both China and other countries. Danshen injection made from the aqueous extract of Danshen which is widely adopted in China is one of the traditional Chinese medicine injections for preventing and treating cardiovascular diseases in most of the time. The present study was carried out on re-evaluating the safety of Danshen injection by determining toxicity after acute and sub-chronic administration in Sprague-Dawley (SD) rats.
In acute toxicity study, rats (10 males and 10 females) were intravenously administered Danshen injection dose of 32g/kg body weight, two times in one day. General behavior, adverse effects and mortality were recorded for up to 14days post treatment. In the sub-chronic study, Danshen injection was given intravenously at the doses of 0, 1.92, 5.76, and 19.20g/kg per day (n=15/group each sex) for 13weeks to rats. Animal body weight and food intakes were observed weekly. Hematological, biochemical parameters and organ weight were determined in all animals at the end of the 13-week administration and 2-week recovery. However, histological examinations were carried out in the control and high-dose groups only.
In acute study, the sign of struggling was observed in some animals at the moment of intravenous administration. No deaths and other signs of toxicity occurred in any of the animals tested during the 14days of the study. In sub-chronic study, Danshen injection did not result to death, adverse effects or dose-dependent changes in food consumption, but had an effect on body weight gain. Some statistically significant differences were observed in hematological and biochemical parameters, as well as in some organ weights of both male and female rats treated with Danshen injection. In these changes, the significant decrease in triglycerides and increase in total bilirubin were considered related to treatment, indicating the lipid-modulating activity of Danshen. Histopathological examinations of the injection site showed that Danshen injection could cause dose-dependent focal inflammation. There was no abnormality of other organs noted in both gross and histopathological examinations.
The results showed that acute or sub-chronic administration of Danshen injection was low or non-toxic in male and female rats, and the no-observed-adverse-effect-level for sub-chronic administration of Danshen injection dose was 5.76g/kg bw/day, which was suggested that it was safe in clinical use.
丹参,中国名为丹参,在中国和其他国家已有数百年的使用历史。丹参注射液是从丹参的水提物制成的,在中国被广泛用于预防和治疗心血管疾病,是传统中药注射液之一。本研究通过测定丹参注射液在 Sprague-Dawley(SD)大鼠急性和亚慢性给药后的毒性,对其安全性进行了重新评估。
在急性毒性研究中,大鼠(雄性 10 只,雌性 10 只)静脉注射丹参注射液剂量为 32g/kg 体重,每天两次。治疗后 14 天内记录一般行为、不良反应和死亡率。在亚慢性研究中,丹参注射液以 0、1.92、5.76 和 19.20g/kg/天(每组雌雄各 15 只)的剂量静脉给药 13 周。每周观察动物体重和食物摄入量。所有动物在给药结束后 13 周和恢复 2 周时测定血液学、生化参数和器官重量。然而,仅对对照组和高剂量组进行了组织学检查。
在急性研究中,一些动物在静脉给药时出现挣扎迹象。在研究的 14 天内,未观察到任何动物死亡或出现其他毒性迹象。在亚慢性研究中,丹参注射液未导致死亡、不良反应或剂量依赖性的食物消耗变化,但对体重增长有影响。一些雄性和雌性大鼠的血液学和生化参数以及某些器官重量发生了统计学上的显著差异。在这些变化中,甘油三酯的显著降低和总胆红素的增加被认为与治疗有关,表明丹参具有调节脂质的活性。注射部位的组织学检查显示,丹参注射液可引起剂量依赖性局灶性炎症。在大体和组织病理学检查中均未发现其他器官异常。
结果表明,丹参注射液急性或亚慢性给药对雄性和雌性大鼠的毒性较低或无毒性,丹参注射液亚慢性给药的无观察到不良反应水平为 5.76g/kg bw/day,提示其在临床应用中是安全的。